[Calculation of direct standard costs in the evaluation of new technologies: application to the treatment of acute myeloblastic leukemias].
Financial incidence of new technology can be approached through the utilization of "direct standard cost". This method allows actualization of prices and permits the integration of new procedures. It is applied to acute non lymphoblastic leukemia.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis / Q000379:methods*; D004059:Diffusion of Innovation; D006801:Humans; D007902:Length of Stay; D015470:Leukemia, Myeloid, Acute / Q000191:economics* / Q000628:therapy; D010357:Patient Isolators / Q000191:economics
Calcul de coûts directs standards dans l'évaluation des technologies nouvelles: application au traitement des leucémies aiguës myéloblastiques.